VTS-72 aims to be the next generation oral fumarate therapy, that may hold potential as a treatment for MS with fewer side effects and other clinical benefits for these patients.
Aiming to submit NDA in 2020-2021.
VTS-72 aims to be the next generation oral fumarate therapy, that may hold potential as a treatment for MS with fewer side effects and other clinical benefits for these patients.
Aiming to submit NDA in 2020-2021.
Ketamine News
January 28, 2021
NeurologyLive
April 28, 2020
NeurologyLive
January 10, 2020
NeurologyLive
October 24, 2019
MS News Today
October 24, 2019
BioWorld
subscription required to view full article
October 23, 2019
MS News Today
January 10, 2020